Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking

Abstract The application of monoclonal antibodies as targeted drugs has revolutionized cancer therapy, yet their efficacy is sometimes limited by toxicities arising from target expression in healthy tissues. Various strategies have emerged to overcome these issues, including the design of antibody-b...

Descripció completa

Dades bibliogràfiques

Autors principals:	Anna Mestre Borras, Hanna Mehari, Athanasios Bitzios, Ivan Zelepukin, Moeen Ud-Din, Tianqi Xu, Sihan Li, Anna Orlova, Vladimir Tolmachev, Stefan Ståhl, Anzhelika Vorobyeva, John Löfblom
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2026-06-01
Col·lecció:	Journal of Biological Engineering
Matèries:	Cetuximab Prodrug Affibody molecule Conditional activation Matriptase Antibody engineering
Accés en línia:	https://doi.org/10.1186/s13036-026-00705-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!